Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of HNC664 in Healthy Subjects
NCT04504448Phase 1Completed
- Sponsor
- Guangzhou Henovcom Bioscience Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HNC664 in solid tumor, pancreatic cancer (PC) and idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Guangzhou Henovcom Bioscience Co., Ltd. Primary endpoints: Number of subjects with adverse events and concomitant medications, Number of subjects with vital sign measurements and 3 more. Started Aug 2020; status: completed.
02
Drugs
HNC664
03
Conditions
solid tumorpancreatic cancer (PC)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04504448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504448.